Sophie Golding

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier et al. · Journal of Clinical Oncology · 2010 · 806 citations

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 688 citations

Phase 1/2, Neuro-oncology, Dose-finding Portion +9

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Alice T. Shaw, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2016 · 195 citations · Full text

Release and interconversion of P2 receptor agonists by human osteoblast‐like cells

Katherine M. Buckley, Sophie Golding, Janet M. Rice et al. · The FASEB Journal · 2003 · 88 citations

P2 Receptor Agonists, Osteoporosis, Cellular Physiology +20